The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances β-cell function but does not inhibit gastric emptying in mice

Endocrinology

Volumn 149, Issue 11, 2008, Pages 5670-5678

  Maida, Adriano ^a   Lovshin, Julie A ^a   Baggio, Laurie L ^a   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; EXENDIN 4; GLUCOSE; INSULIN; OXYNTOMODULIN; STREPTOZOCIN; THAPSIGARGIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL FUNCTION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STOMACH EMPTYING;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CRICETINAE; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; EATING; GASTRIC EMPTYING; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXYNTOMODULIN; RATS; RECEPTORS, GLUCAGON;

EID: 54349119151     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0336     Document Type: Article

References (55)

1. Irwin DM 2001 Molecular evolution of proglucagon. Regul Pept 98:1-12
2. Irwin DM, Wong J 1995 Trout and chicken proglucagon: alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2. Mol Endocrinol 9:267-277
3. Chen YE, Drucker DJ 1997 Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 272:4108-4115
4. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF 1986 Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880-11889
5. Patzelt C, Tager HS, Carroll RJ, Steiner DF 1979 Identification and processing of proglucagon in pancreatic islets. Nature 282:260-266
6. Dhanvantari S, Seidah NG, Brubaker PL 1996 Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 10:342-355
7. Drucker DJ 2001 The glucagon-like peptides. Endocrinology 142:521-527
8. Bataille D, Tatemoto K, Gespach C, Jornvall H, Rosselin G, Mutt V 1982 Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett 146:79-86
9. Jarrousse C, Audousset-Puech MP, Dubrasquet M, Niel H, Martinez J, Bataille D 1985 Oxyntomodulin (glucagon-37) and its C-terminal octapeptide inhibit gastric acid secretion. FEBS Lett 188:81-84
10. Jarrousse C, Niel H, Audousset-Puech M-P, Martinez J, Bataille D 1986 Oxyntomodulin and its C-terminal octapeptide inhibit liquid meal-stimulated acid secretion. Peptides 7:253-256
11. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV 1988 Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 21:151-166
12. Schjoldager BTG, Baldissera FG, Mortensen PE, Holst JJ, Christiansen J 1988 Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 18:499-503
13. Parlevliet ET, Heijboer AC, Schroder-van der Elst JP, Havekes LM, Romijn JA, Pijl H, Corssmit EP 2008 Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 294:E142-E147
14. Collie NL, Zhu Z, Jordan S, Reeve Jr JR 1997 Oxyntomodulin stimulates intestinal glucose uptake in rats. Gastroenterology 112:1961-1970
15. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR 2001 Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244-4250
16. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR 2002 Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283:E1173-E1177
17. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR 2004 Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695
18. Baggio LL, Huang Q, Brown TJ, Drucker DJ 2004 Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546-558
19. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR 2006 Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30:1729-1736
20. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ 2007 Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117:143-152
21. Baggio LL, Huang QH, Cao X, Drucker DJ 2008 The long-acting albumin-exendin-4 GLP-1R agonist CJC-1134 engages central and peripheral mechanisms regulating glucose homeostasis. Gastroenterology 134:1137-1147
22. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X 1999 Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331
23. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ 2003 Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478
24. Lamont BJ, Drucker DJ 2008 Differential anti-diabetic efficacy of incretin agonists vs. DPP-4 inhibition in high fat fed mice. Diabetes 57:190-198
25. + channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49:424-430
26. Ahren B 2004 Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 286:R269-R272
27. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA 2007 Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:4965-4973
28. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF 1987 Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438
29. Wang Q, Li L, Xu E, Wong V, Rhodes CJ, Brubaker PL 2004 Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic (INS-1) β-cells. Diabetologia 47:478-487
30. Toyoda K, Okitsu T, Yamane S, Uonaga T, Liu X, Harada N, Uemoto S, Seino Y, Inagaki N 2008 GLP-1 receptor signaling protects pancreatic β-cells in intraportal islet transplant by inhibiting apoptosis. Biochem Biophys Res Commun 367:793-798
31. Yusta B, Baggio LL, Estall JE, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z, Drucker DJ 2006 GLP-1 receptor activation improves β-cell function and survival following induction of endoplasmic reticulum stress. Cell Metabolism 4:391-406
32. Yano T, Liu Z, Donovan J, Thomas MK, Habener JF 2007 Stromal cell derived factor-1 (SDF-1)/CXCL12 attenuates diabetes in mice and promotes pancreatic β-cell survival by activation of the prosurvival kinase Akt. Diabetes 56:2946 -2957
33. Potts JT, Gardella TJ 2007 Progress, paradox, and potential: parathyroid hormone research over five decades. Ann NY Acad Sci 1117:196-208
34. Citri A, Yarden Y 2006 EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516
35. Dinulescu DM, Cone RD 2000 Agouti and agouti-related protein: analogies and contrasts. J Biol Chem 275:6695-6698
36. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP 1995 Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7:2294-2300
37. Kastin AJ, Akerstrom V 2003 Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27:313-318
38. Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ 1996 Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med 2:1254-1258
39. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR 1996Arole for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72
40. Kinzig KP, D'Alessio DA, Seeley RJ 2002 The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 22:10470-10476
41. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA 2002 Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269-279
42. Drucker DJ 2003 Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929-2940
43. Drucker DJ, Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
44. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR 2003 Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696-4701
45. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Pennacarrillo ML, Ulusoy NB 1997 Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273:G920-G927
46. Wettergren A, Wojdemann M, Holst JJ 1998 Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275:G984-G992
47. Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ 1989 Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 34:1411-1419
48. Barragan JM, Rodriguez RE, Blazquez E 1994 Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36 amide) in rats. Am J Physiol 266:E459-E466
49. Barragan JM, Rodriguez RE, Eng J, Blazquez E 1996 Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regulatory Peptides 67:63-68
50. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK 2002 Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43-52
51. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK 2003 Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23:2939-2946
52. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M 2003 Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144:2242-2252
53. Sowden GL, Drucker DJ, Weinshenker D, Swoap SJ 2007 Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am J Physiol Regul Integr Comp Physiol 292:R962-R970
54. Chaudhri OB, Parkinson JR, Kuo YT, Druce MR, Herlihy AH, Bell JD, Dhillo WS, Stanley SA, Ghatei MA, Bloom SR 2006 Differential hypothalamic neuronal activation after peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun 350:298-306
55. s. J Pharmacol Exp Ther 322:148-154